Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie

seekingalpha07-23

Cerevel Therapeutics (NASDAQ:CERE) rose 1.2% as investors appeared to be gaining confidence that the Federal Trade Commission will approve its planned sale to AbbVie (NYSE:ABBV). The deal spread ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453717486?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg","is_english":true,"pubTime":"2024-07-23 04:03","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2453717486","market":"hk","top_or_hot":-1,"title":"Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie","media":"seekingalpha","content":"<div>\n<p>Cerevel Therapeutics (NASDAQ:CERE) rose 1.2% as investors appeared to be gaining confidence that the Federal Trade Commission will approve its planned sale to AbbVie (NYSE:ABBV). The deal spread ...</p>\n\n<a href=\"https://seekingalpha.com/news/4126455-cerevel-therapeutics-gains-as-investors-appear-more-confident-on-ftc-approval-for-abbvie\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-23 04:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4126455-cerevel-therapeutics-gains-as-investors-appear-more-confident-on-ftc-approval-for-abbvie><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cerevel Therapeutics (NASDAQ:CERE) rose 1.2% as investors appeared to be gaining confidence that the Federal Trade Commission will approve its planned sale to AbbVie (NYSE:ABBV). The deal spread ...</p>\n\n<a href=\"https://seekingalpha.com/news/4126455-cerevel-therapeutics-gains-as-investors-appear-more-confident-on-ftc-approval-for-abbvie\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1244550221.USD","symbol_name":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","start_time":0,"source_url":"https://seekingalpha.com/news/4126455-cerevel-therapeutics-gains-as-investors-appear-more-confident-on-ftc-approval-for-abbvie","article_id":"2453717486","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666845/image_1307666845.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453717486","pubTimestamp":1721678594,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Cerevel Therapeutics  rose 1.2% as investors appeared to be gaining confidence that the Federal Trade Commission will approve its planned sale to AbbVie . The deal spread narrowed to its lowest since the $8.7 billion acquisition of Cerevel  was announced in earlier December at least party as one sell-side broker appeared to be more optimistic that the antitrust regulator wouldn't move to block the combination, traders told Seeking Alpha on Monday. Today's gain follows after Cerevel  rose 8% last week even after a report from CTFN earlier this month that the staff of the FTC's Mergers 1 section was said to be apparently considering a recommendation to block deal.  There was also a Capitol Forum report last month that AbbVie  and Cerevel  were gaining confidence about the FTC clearing the deal. Cerevel  and AbbVie disclosed in February that they received second requests from the FTC for additional information regarding their planned deal. In early December,","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LENZ":"Therapeutics","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4585":"ETF&股票定投概念","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4534":"瑞士信贷持仓","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","BK4139":"生物科技","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4581":"高盛持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4566":"资本集团","CERE":"Cerevel Therapeutics Holdings, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4588":"碎股","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4550":"红杉资本持仓","ABBV":"艾伯维公司","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","FTC":"First Trust Large Cap Growth Opp","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC"},"translate_title":"Cerevel Therapeutics上涨，投资者对FTC批准艾伯维(AbbVie)更有信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"LENZ":1,"CERE":1,"FTC":1},"content_text":"Cerevel Therapeutics (NASDAQ:CERE) rose 1.2% as investors appeared to be gaining confidence that the Federal Trade Commission will approve its planned sale to AbbVie (NYSE:ABBV). The deal spread narrowed to its lowest since the $8.7 billion acquisition of Cerevel (CERE) was announced in earlier December at least party as one sell-side broker appeared to be more optimistic that the antitrust regulator wouldn't move to block the combination, traders told Seeking Alpha on Monday. Today's gain follows after Cerevel (CERE) rose 8% last week even after a report from CTFN earlier this month that the staff of the FTC's Mergers 1 section was said to be apparently considering a recommendation to block deal.  There was also a Capitol Forum report last month that AbbVie (ABBV) and Cerevel (CERE) were gaining confidence about the FTC clearing the deal. Cerevel (CERE) and AbbVie disclosed in February that they received second requests from the FTC for additional information regarding their planned deal. In early December,","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453717486"}